Eckert & Ziegler have signed an agreement on the supply of Actinium-225. Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands. "Since our early days, POINT has placed a significant focus on radioligand manufacturing and isotope supply, two areas we believe have been overlooked by many in the industry," said Joe McCann, Ph.D., CEO of POINT Biopharma. "This agreement with Eckert & Ziegler contributes to our continued research and development with Actinium-225, an exciting therapeutic isotope. We are looking forward to launching our first Ac-225 phase 1 trial for the next generation PSMA-targeted PNT2001 program later this year."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PNT:
- Point Biopharma expects cash to fund operations into 2026
- Point Biopharma reports Q4 EPS $1.53 vs. (16c) last year
- POINT Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights
- POINT Biopharma Confirms No Disruptions to the Manufacturing and Clinical Supply for the 177Lu-PNT2002 SPLASH Trial, a Phase 3 Study in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Point Biopharma: SPLASH trial not experiencing manufacturing, drug supply issues